according to the OSHA Hazard Communication Standard



Posaconazole Injection Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 03/20/2023

 8.8
 09/26/2023
 22519-00023
 Date of first issue: 10/16/2014

SECTION 1. IDENTIFICATION

Product name : Posaconazole Injection Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Skin sensitization : Category 1

Reproductive toxicity : Category 2

Specific target organ toxicity

- repeated exposure (Oral) ous sys

: Category 1 (Adrenal gland, Bone marrow, Kidney, Liver, Nerv-

ous system, Reproductive organs)

GHS label elements

Hazard pictograms





Signal Word : Danger

Hazard Statements : H317 May cause an allergic skin reaction.

H361d Suspected of damaging the unborn child.

H372 Causes damage to organs (Adrenal gland, Bone marrow, Kidney, Liver, Nervous system, Reproductive organs) through

prolonged or repeated exposure if swallowed.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe mist or vapors. P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product. P272 Contaminated work clothing must not be allowed out of

the workplace.

according to the OSHA Hazard Communication Standard



Posaconazole Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 8.8 09/26/2023 22519-00023 Date of first issue: 10/16/2014

P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of soap and water. P308 + P313 IF exposed or concerned: Get medical attention. P333 + P313 If skin irritation or rash occurs: Get medical atten-

tion.

P363 Wash contaminated clothing before reuse.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
.betaCyclodextrin, sulfobutyl ethers,	182410-00-0	>= 30 - < 50
sodium salts		
Posaconazole	171228-49-2	>= 1 - < 5

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.: Flush eyes with water as a precaution.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

Diarrhea Fever

according to the OSHA Hazard Communication Standard



Posaconazole Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 8.8 09/26/2023 22519-00023 Date of first issue: 10/16/2014

delayed Headache

Nausea Vomiting

May cause an allergic skin reaction. Suspected of damaging the unborn child.

Causes damage to organs through prolonged or repeated

exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides Sulfur oxides

Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

: Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material

can be pumped, store recovered material in appropriate

container.

according to the OSHA Hazard Communication Standard



Posaconazole Injection Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 03/20/2023

 8.8
 09/26/2023
 22519-00023
 Date of first issue: 10/16/2014

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not get on skin or clothing. Do not breathe mist or vapors.

Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Posaconazole	171228-49-2	TWA	300 μg/m3 (OEB 2)	Internal

Engineering measures : Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Laboratory operations do not require special containment.

according to the OSHA Hazard Communication Standard



Posaconazole Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 8.8 09/26/2023 22519-00023 Date of first issue: 10/16/2014

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to

maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided

by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other

circumstance where air purifying respirators may not provide

adequate protection.

Hand protection

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection

Hygiene measures

Work uniform or laboratory coat.

If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke.

Contaminated work clothing should not be allowed out of the

workplace.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution

Color : Colorless to pale yellow

Odor : odorless

Odor Threshold : No data available

pH : 2.6

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

according to the OSHA Hazard Communication Standard



Posaconazole Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 09/26/2023 22519-00023 Date of first issue: 10/16/2014 8.8

No data available Evaporation rate

Flammability (solid, gas) Not applicable

Flammability (liquids) No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure No data available

Relative vapor density No data available

Relative density No data available

Density 1.15 g/cm³

Solubility(ies)

Water solubility No data available

Partition coefficient: n-

octanol/water

Not applicable

Autoignition temperature No data available

No data available Decomposition temperature

Viscosity

No data available Viscosity, kinematic

Explosive properties Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Molecular weight No data available

Particle size Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity Not classified as a reactivity hazard. Chemical stability Stable under normal conditions. Can react with strong oxidizing agents.

Possibility of hazardous reac-

Conditions to avoid None known. Incompatible materials Oxidizing agents

Hazardous decomposition

products

No hazardous decomposition products are known.

according to the OSHA Hazard Communication Standard



Posaconazole Injection Formulation

Version 8.8 Revision Date: 09/26/2023

SDS Number: 22519-00023

Date of last issue: 03/20/2023 Date of first issue: 10/16/2014

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

Components:

.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:

Acute oral toxicity : LD50 (Rat): > 8,800 mg/kg

Posaconazole:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

LD50 (Mouse): > 3,000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Posaconazole:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Posaconazole:

Species : Rabbit

Result : Mild eye irritation

Respiratory or skin sensitization

Skin sensitization

May cause an allergic skin reaction.

according to the OSHA Hazard Communication Standard



Posaconazole Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 8.8 09/26/2023 22519-00023 Date of first issue: 10/16/2014

Respiratory sensitization

Not classified based on available information.

Components:

.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:

Assessment : Probability or evidence of skin sensitization in humans

Posaconazole:

Test Type : Magnusson-Kligman-Test

Routes of exposure : Skin contact Species : Guinea pig Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Posaconazole:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Cell type: Bone marrow Application Route: Intravenous

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Posaconazole:

Species : Rat

Application Route : oral (feed)
Exposure time : 2 Years
Result : positive

Remarks : The mechanism or mode of action is not relevant in humans.

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : positive

Remarks : The mechanism or mode of action is not relevant in humans.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

according to the OSHA Hazard Communication Standard



Posaconazole Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 8.8 09/26/2023 22519-00023 Date of first issue: 10/16/2014

OSHANo component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Intravenous injection

Result: negative

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Intravenous injection

Result: negative

Posaconazole:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, male

General Toxicity Parent: NOAEL: 180 mg/kg body weight

Symptoms: No effects on mating performance.

Result: negative

Test Type: Fertility/early embryonic development

Species: Rat, female

General Toxicity Parent: NOAEL: 45 mg/kg body weight

Symptoms: No effects on mating performance.

Result: negative

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat, female Application Route: Oral

Developmental Toxicity: LOAEL: 29 mg/kg body weight Result: Fetotoxicity., Malformations were observed.

Test Type: Embryo-fetal development

Species: Rabbit, female

Developmental Toxicity: LOAEL: 40 mg/kg body weight

Result: Fetotoxicity.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

STOT-single exposure

Not classified based on available information.

according to the OSHA Hazard Communication Standard



Posaconazole Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 8.8 09/26/2023 22519-00023 Date of first issue: 10/16/2014

STOT-repeated exposure

Causes damage to organs (Adrenal gland, Bone marrow, Kidney, Liver, Nervous system, Reproductive organs) through prolonged or repeated exposure if swallowed.

Components:

Posaconazole:

Routes of exposure : Ingestion

Target Organs : Adrenal gland, Bone marrow, Kidney, Liver, Reproductive

organs, Nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Posaconazole:

Species : Rat, female
LOAEL : 5 mg/kg
Application Route : Oral
Exposure time : 6 Months

Target Organs : Adrenal gland, Lungs, Heart, Liver, spleen, Kidney, Ovary

Species : Dog LOAEL : 3 mg/kg Application Route : Oral Exposure time : 392 Days

Target Organs : Lungs, Liver, Brain, small intestine, Adrenal gland, Spinal

cord, lymphoid tissue

Species : Monkey
LOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 1 Months

Target Organs : Bone marrow, Adrenal gland, Lymph nodes, Blood

Species : Dog LOAEL : 3 mg/kg Application Route : Oral Exposure time : 56 Weeks

Target Organs : Adrenal gland, Bone marrow, Kidney, Nervous system,

spleen, thymus gland, Testis, lymphoid tissue

Species : Monkey
LOAEL : 180 mg/kg
Application Route : Oral
Exposure time : 12 Months

Target Organs : Blood, Gastrointestinal tract, spleen

Species : Monkey
LOAEL : 8 mg/kg
Application Route : Intravenous
Exposure time : 1 Months

according to the OSHA Hazard Communication Standard



Posaconazole Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 8.8 09/26/2023 22519-00023 Date of first issue: 10/16/2014

Target Organs : Cardio-vascular system, Lungs, Adrenal gland, Blood

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Posaconazole:

Ingestion : Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver

effects, Rash, pruritis, Diarrhea, hypertension, neutropenia,

electrolyte imbalance

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 220 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 96 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Selenastrum capricornutum (green algae)): > 100 mg/l

Exposure time: 72 h

Posaconazole:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.95 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.276 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): >

0.509 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.206 mg/l

Exposure time: 33 d

Method: OECD Test Guideline 210

according to the OSHA Hazard Communication Standard



Posaconazole Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 8.8 09/26/2023 22519-00023 Date of first issue: 10/16/2014

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.244 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50 (Natural microorganism): > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Persistence and degradability

Components:

Posaconazole:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 28 h

Method: OECD Test Guideline 314

Stability in water : Degradation half life (DT50): > 30 d

Method: OECD Test Guideline 111

Bioaccumulative potential

Components:

Posaconazole:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

Bioconcentration factor (BCF): 20 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

log Pow: 4.15

Mobility in soil

Components:

Posaconazole:

Distribution among environ-

mental compartments

: log Koc: 5.52

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

according to the OSHA Hazard Communication Standard



Posaconazole Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 8.8 09/26/2023 22519-00023 Date of first issue: 10/16/2014

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Respiratory or skin sensitization

Reproductive toxicity

Specific target organ toxicity (single or repeated exposure)

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Water 7732-18-5 .beta.-Cyclodextrin, sulfobutyl ethers, sodium salts 182410-00-0

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

according to the OSHA Hazard Communication Standard



Posaconazole Injection Formulation


Version Revision Date: SDS Number: Date of last issue: 03/20/2023 8.8 09/26/2023 22519-00023 Date of first issue: 10/16/2014

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



Special hazard

HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance: ELx - Loading rate associated with x% response: EmS - Emergency Schedule: ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office

according to the OSHA Hazard Communication Standard



Posaconazole Injection Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 03/20/2023

 8.8
 09/26/2023
 22519-00023
 Date of first issue: 10/16/2014

of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 09/26/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8